stockrowNeogen Corporation
NEOG Healthcare Medical Devices
Neogen Corporation’s revenue for fiscal 2026 (year ended May 2026) was $870.4 million, down 2.72% from fiscal 2025.
- Revenue
- +6.50%
- EPS
- −129.4%
- Free cash flow
- +135.6%
- Total debt
- −2.31%
Quarter to August 2026, against a year earlier
Follow NEOG
Alert me
Neogen Corporation (NEOG) EBITDA
Neogen Corporation's EBITDA for fiscal 2026 was $102.3M, down 25.1% from $136.6M in fiscal 2025. Over the twelve months to 31 August 2026 it was $116.5M. Over the past ten years it has ranged from $63.8M (fiscal 2015) to $183.8M (fiscal 2024); the current reading is higher than 75% of that period. Neogen Corporation ranks 26th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $102.3M | (25.11%) |
| FY2025 | $136.6M | (25.68%) |
| FY2024 | $183.8M | 40.62% |
| FY2023 | $130.7M | 57.96% |
| FY2022 | $82.8M | (13.09%) |
| FY2021 | $95.2M | 10.81% |
| FY2020 | $85.9M | 0.23% |
| FY2019 | $85.7M | (1.76%) |
| FY2018 | $87.3M | 9.56% |
| FY2017 | $79.6M | 16.14% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Aug 2026 | $29.1M | (24.76%) |
| May 2026 | $38.7M | 48.20% |
| Feb 2026 | $26.1M | 15.34% |
| Nov 2025 | $22.6M | 51.85% |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ITGR Integer Holdings Corporation compare | $296.5M |
| TMDX TransMedics Group, Inc. compare | $126.9M |
| NEOG Neogen Corporation | $116.5M |
| UFPT UFP Technologies, Inc. compare | $116.0M |
| INSP Inspire Medical Systems, Inc. compare | $33.2M |
| AXGN AxoGen, Inc. compare | −$4.1M |
| ESTA Establishment Labs Holdings Inc. compare | −$8.1M |
| ALMR Alamar Biosciences, Inc. compare | −$38.4M |
| BFLY Butterfly Network, Inc. compare | −$51.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on NEOG
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement